医药魔方 / 最新资讯 / 正文

新药上市首年销售表现最好的16个药物

青瓦 青瓦 来源:医药魔方
2018-12-03
新药 丙肝
原文

哪些新药能在上市首年(前12个自然月)就进入了“重磅炸弹”俱乐部?近年来上市的丙肝药物无疑是医学和商业的“双料冠军”。


《Nature Review Drug Discovery》近日发布的一篇行业观察文章显示,新药上市首年销售最好的16个药物中,Harvoni与Sovaldi双双入选且高居榜单第一、二名,除此之外,还有Epclusa 及Incivek 这两款丙肝药物进入榜单。


2013年吉利德推出的Sovaldi因其高昂的定价成为了媒体争相报道的“头条”,而后推出的二联复方Harvoni更是创下了新药上市的记录,在美国市场的前四个季度销售额超过100亿美元。


在抗病毒领域之外,多发性硬化症(MS)是另一个容易诞生“重磅炸弹”的领域,比如百健最近上市的口服药物Tecfidera以及罗氏的CD20单抗Ocrevus。


1997年上市的他汀类药物Lipitor是首个上市前12个月销售过10亿美元的产品。尽管它在2011年失去了专利保护,但截止到2017年,它的销售额高达1620亿美元。


另一个老产品是辉瑞(Pharmacia)的COX2抑制剂Celebrex,此外由于安全问题而被撤回的COX2抑制剂Vioxx也进入了前十名。


以下是新药上市前12个月销售最好的16个药物名单。


上市前12个月销售最好的16个药物(单位:亿美元)


备注:此分析数据来自EvaluatePharma,不包括仿制药,现有产品和疫苗的组合。 括号内表示未调整数据,括号外是基于通胀调整后的数据。

参考资料:The industry’s biggest drug launches


机器翻译

Which new drugs can enter the "blockbuster" club in the first year of listing (the first 12 natural months)?Hepatitis C drugs marketed in recent years are undoubtedly the "double champion" of medicine and commerce.

An industry observation article published recently by Nature Review Drug Discovery shows that Harvoni and Sovaldi were both selected and ranked first and second in the list for the first year of the new drug market. In addition, Epclusa and Incivek, two hepatitis C drugs, entered the list.

The Sovaldi launched by Gilead in 2013 became the "headline" of media coverage because of its high pricing, and the subsequent launch of the second compound Harvoni set a record for the launch of new drugs, with sales exceeding US $10 billion in the first four quarters of the US market.

Outside of the antiviral field, multiple sclerosis (MS) is another area that is prone to the birth of "blockbusters", such as Baijian's recently marketed oral drug Tecfidera and Roche's CD20 monoclonal antibody Ocrevus.

Lipitor, a statin marketed in 1997, was the first product sold for $1 billion in the 12 months prior to its launch.Although it lost patent protection in 2011, it had sales of $162 billion as of 2017.

Another old product is Celebrex, the COX2 inhibitor of Pfizer (Pharmacia), and in addition the COX2 inhibitor that was withdrawn due to safety concerns Vioxx also entered the top ten.

The following is the list of the best 16 drugs sold in the 12 months before the launch of the new drug.

The best 16 drugs (unit: $100 million) sold in the 12 months prior to marketing

Remarks: Data for this analysis are from EvaluatePharma, excluding combinations of generic drugs, existing products, and vaccines.Unadjusted data are indicated in parentheses and are based on inflation-adjusted data.

References: The industry's biggest drug clouches

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号